PDCD1 and glioblastoma: MHC-II-restricted antigen presentation by cells of the myeloid compartment, particularly those infiltrating from the periphery but not microglia alone, is required for the response to ICIs and correlates with favorable clinical outcomes in GBM patients receiving anti-PD-1 therapy [63].